David Mitchell
6.2K posts

David Mitchell
@DavidP4AD
Diagnosed w/multiple myeloma 2010. Completely dependent on innovation & new drugs for survival. Fighting for affordable prices. Founder: @P4AD_ & @P4ADNOW

Revlimid is a cancer treatment that is marketed by Bristol Myers Squibb. It carries a list price of over $18,000 per cycle (given every 28 days). We investigated the patenting strategies around Revlimid. Here's what we found: 📄206 patent applications have been filed 📄117 patents have been granted These granted patents amount to 42.9 years of patent protection, approximately 2X the 20-year limit intended by the U.S. patent system. They have been used to block unlimited generic entry until January 2026, providing up to nearly 6 years of extra market exclusivity.


















